1. Home
  2. PRCH vs DSGN Comparison

PRCH vs DSGN Comparison

Compare PRCH & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRCH

Porch Group Inc.

HOLD

Current Price

$11.06

Market Cap

848.9M

Sector

Technology

ML Signal

HOLD

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$14.20

Market Cap

819.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCH
DSGN
Founded
2012
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
848.9M
819.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
PRCH
DSGN
Price
$11.06
$14.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
4
Target Price
$18.63
$15.25
AVG Volume (30 Days)
2.2M
493.9K
Earning Date
04-28-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
N/A
EPS
N/A
N/A
Revenue
$482,414,000.00
N/A
Revenue This Year
$4.15
N/A
Revenue Next Year
$17.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.18
N/A
52 Week Low
$6.36
$3.11
52 Week High
$19.44
$17.25

Technical Indicators

Market Signals
Indicator
PRCH
DSGN
Relative Strength Index (RSI) 72.27 59.24
Support Level $8.93 $9.71
Resistance Level $16.67 $17.25
Average True Range (ATR) 0.72 1.16
MACD 0.29 0.01
Stochastic Oscillator 88.62 42.56

Price Performance

Historical Comparison
PRCH
DSGN

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

Share on Social Networks: